bimekizumab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
monoclonal antibodies (humanized origin); interleukin 5478 1418205-77-2

Description:

MoleculeDescription

Molfile

Synonyms:

  • bimekizumab
  • bimzelx
  • UCB4940
  • bimekizumab (genetical recombination)
Bimekizumab is a humanised IgG1/kappa monoclonal antibody that selectively binds with high affinity to IL-17A, IL-17F and IL-17AF cytokines, blocking their interaction with the IL-17RA/IL-17RC receptor complex. Elevated concentrations of IL-17A and IL-17F have been implicated in the pathogenesis of several immune-mediated inflammatory diseases including plaque psoriasis. Bimekizumab inhibits these proinflammatory cytokines, resulting in the normalization of skin inflammation and as a consequence improvement in clinical symptoms associated with psoriasis. From in vitro models, bimekizumab was shown to inhibit psoriasis-related gene expression and cytokine production to a greater extent than inhibition of IL-17A alone.
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Aug. 20, 2021 EMA UCB Pharma S.A.
Jan. 20, 2022 PMDA UCB JAPAN CO., LTD.

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L04AC21 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
IMMUNOSUPPRESSANTS
IMMUNOSUPPRESSANTS
Interleukin inhibitors

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Plaque psoriasis indication 200965009
Pustular psoriasis indication 200973000
Erythrodermic psoriasis indication 200977004
Inflammatory bowel disease contraindication 24526004 DOID:0050589
Upper respiratory tract infection contraindication 54150009
Oral candidiasis contraindication 79740000 DOID:14262
Active tuberculosis contraindication 427099000




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Interleukin-17A Cytokine ANTIBODY BINDING Kd 11.46 DRUG LABEL DRUG LABEL
Interleukin-17F Cytokine ANTIBODY BINDING Kd 10.55 DRUG LABEL DRUG LABEL
Interleukin-17AF Cytokine ANTIBODY BINDING Kd 10.59 DRUG LABEL DRUG LABEL

External reference:

IDSource
09495UIM6V UNII
C4519734 UMLSCUI
CHEMBL4297700 ChEMBL_ID
DB12917 DRUGBANK_ID
D11550 KEGG_DRUG
9411 IUPHAR_LIGAND_ID
018864 NDDF
C000625981 MESH_SUPPLEMENTAL_RECORD_UI
9878 INN_ID

Pharmaceutical products:

None